The Company has more than 30 proprietary and partnered product candidates in development
Ablynx organises webcasts for analysts and investors on the occasion of financial results
Ablynx is listed on Euronext Brussels under the ticker symbol ABLX.
ABLYNX ANNOUNCES HALF-YEAR RESULTS FOR 2015
27 August 2015
ABLYNX TO HOST WEBCAST FOR ITS 2015 HALF-YEAR RESULTS ON 27 AUGUST
19 August 2015
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
14 August 2015
Ablynx’s proprietary Nanobody platform allows for the rapid generation and large-scale production of novel biological therapeutics that have potential in a wide range of human diseases.